## 

## 

## 

|Objective|s and|activities|||
|---|---|---|---|---|
||||SORP reference||
|Summary|ofthe purposes ofthe||Pere 1.17|1.To relieve sickness and to preserve<br>and|
|charity as|set out|in its||protect health by providing<br>support to chronic|
|governing|document|||lymphocytic<br>leukaemia<br>(CLL) patients and their|
|||||carers. (CLL includes<br>similar related conditions|
|||||such as SLL).|
|||||2.To advance<br>public education<br>in CLL related|
|||||matters<br>primarily<br>in the UK through<br>publications|
|||||and the internet.|
|||||3.To promote and support<br>scientific research|
|||||into the treatment<br>and care of all CLL patients.|
|Summary<br>in relation|ofthe main activities<br> to those purposes for||Para 1.17and<br>1.19|1.The provision of up to date and accessible<br>information<br>about CLL, the range oftreatments|
|the public|benefit,|in particular,||currently<br>available<br>and the latest research<br>into|
|the activities, projects or||||the care and treatment<br>of CLL, through<br>its|
|services identified||in the||website, member conferences,<br>publications<br>and|
|accounts.||||a telephone<br>helpline.|
|||||2.The development<br>ofopportunities<br>to share|
|||||understanding<br>and personal experience<br>by|
|||||bringing<br>CLL patients together,<br>and by creating|
|||||mutual<br>support groups and networks.|
|||||3.Acting as a voice for CLL patients,|
|||||representing<br>their interests<br>with the|
|||||pharmaceutical<br>industry,<br>clinicians,<br>NHS, cancer|
|||||care policy and drug regulatory<br>authorities,|
|||||funding<br>and commissioning<br>groups and|
|||||Government.|
|||||4.The promotion<br>ofawareness<br>of CLLSA,|
|||||together with its role amongst<br>health care|
|||||providers<br>and decision makers,<br>providers of non-|
|||||healthcare<br>products<br>and services, other blood|
|||||cancer patient groups and the wider public.|





## 

## 



||treatment<br>ofCLL, and by key players|
|---|---|
||directly involved<br>in the development<br>of|
||the preventative<br>vaccines that are seen|
||as a way ofeventually<br>establishing<br>some|
||form ofcontrol over the Covid-19|
||pandemic.<br>The information<br>thus provided|
||has proved<br>vital<br>in offering to CLL|
||patients and their supporters,<br>clear and|
||knowledgeable<br>guidance as to how the|
||measures<br>taken will have impacted<br>on|
||their particular<br>circumstances.|
|3.|Continued<br>its work with the Blood Cancer|
||Alliance and with Cancer52 to promote|
||the interests ofblood cancer generally,|
||and CLL in particular|
|4.|Continued<br>to develop<br>partnering|
||arrangements<br>with major pharmaceutical|
||companies<br>to offer key insights<br>into the|
||way in which treatments<br>impact on the|
||lives and wellbeing<br>ofpatients.|
|The Charity continued<br>to benefit from donations||
|and fundraising<br>activities that were undertaken||
|by its supporters<br>despite the limitations<br>that were||
|placed|on these activities as a result ofthe|
|restrictions<br>put in place by HM Government<br>to||
|combat|the pandemic.|
|The Charity continued<br>to benefit also from||
|funding|provided<br>by grant making organisations|
|and by|the pharmaceutical<br>industry.|



## 


## 



## 

## 



## 

|You ma|choose to include further|statements|where relevant about:|
|---|---|---|---|
|Policies|and procedures|Para 1.51||
|adopted|for the induction<br>and|||
|training|oftrustees|||
|The charity's<br>organisational||Para 1.51||
|structure|and any wider network|||
|with which the charity works||||
|Relationship<br>with any related||Para 1.51||
|parties||||
|Other||||



## 

## 

## 




## 

## 


## 

## 

## 

## 

## 

## 












## 

## 

##